7:00 PM
 | 
Feb 07, 2013
 |  BC Extra  |  Clinical News

Lilly discontinues tabalumab for RA

Eli Lilly and Co. (NYSE:LLY) discontinued development of tabalumab to treat rheumatoid arthritis due to lack of efficacy in futility analyses of both the Phase III FLEX-M and...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >